Nutrition 21 (NXXI) Reports Chromax(R) Reduces Hunger, Food Intake and Cravings
Nutrition 21, Inc. (Nasdaq: NXXI) reported today that results of a randomized, double-blind, placebo-controlled clinical study showed that Nutrition 21's Chromax(R) chromium picolinate significantly reduced hunger levels by 24%, food intake by 25%, and also reduced cravings for high-fat foods in adult non-diabetic overweight women.
Nutrition 21, Inc., a nutritional bioscience company, develops, markets, and distributes clinically substantiated nutritional supplements in the United States.
Nutrition 21, Inc., a nutritional bioscience company, develops, markets, and distributes clinically substantiated nutritional supplements in the United States.
You May Also Be Interested In
- Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
- Dow Chemical (DOW) Wins $2.16B in K-Dow Arbitration
- Mylan (MYL) Launches Generic Bonviva Tabs (RHHBY) in Italy & the U.K.
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
